LAKE FOREST

Assertio Reports First Quarter 2024 Financial Results

Retrieved on: 
Monday, May 6, 2024
Video game

LAKE FOREST, Ill., May 06, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Rolvedon net product sales increased to $14.5 million in the first quarter 2024, from $11.0 million in the fourth quarter 2023, (the first full quarter of Rolvedon sales at Assertio) driven by volume growth.
  • Indocin net product sales in the first quarter 2024 were $8.7 million, decreased from $10.8 million in the fourth quarter 2023, driven by generic competition that affected both volume and pricing.
  • Adjusted EBITDA was $7.4 million in the first quarter 2024, increased from $4.5 million in the fourth quarter 2023, primarily due to the impact of lower SG&A expense.
  • Assertio reiterated its 2024 operating guidance as announced on March 11, 2024:
    Assertio’s management will host a conference call to discuss its first quarter 2024 financial results today:

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

Retrieved on: 
Thursday, May 2, 2024
Johns Hopkins University, University, Mayo Clinic, Cancer, SOS, American College, Case Western Reserve University, AUC, ACG, Esophageal cancer, Prevalence, Methylation, Risk, Barrett's esophagus, Cleveland Clinic, American Journal, Lucid, Adenocarcinoma, National Cancer Institute, NPV, NGS, University of North Carolina, Gold, Detection, EGD, Patient, Research report, NCI, PPV, Medicare, Manuscript, GERD, Guideline, Gastroesophageal reflux disease, Medical imaging

NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored, prospective, multicenter clinical validation study assessing the performance of Lucid's EsoGuard® Esophageal DNA Test on samples collected with its EsoCheck® Esophageal Cell Collection Device. This case-control study, led by Case Western Reserve University's Amitabh Chak, M.D., was funded through the NCI's Barrett's Esophagus Translational Research Network (BETRNet), and included renowned investigators from leading academic medical centers, including Case Western Reserve University, Mayo Clinic, Johns Hopkins University, Washington University in St. Louis, University of North Carolina, and Cleveland Clinic. EsoGuard demonstrated unprecedented early precancer detection compared to the gold standard of upper endoscopy (EGD). The manuscript, entitled Multicenter, Prospective Trial of Non-Endoscopic Biomarker-Driven Detection of Barrett's Esophagus And Esophageal Adenocarcinoma, was published in the American Journal of Gastroenterology, the leading clinical journal covering gastroenterology published on behalf of the American College of Gastroenterology (ACG).

Key Points: 
  • EsoGuard demonstrated unprecedented early precancer detection compared to the gold standard of upper endoscopy (EGD).
  • Dr. Aklog concluded, "The publication of the BETRNet study is the culmination of a period of rapid expansion of EsoGuard's clinical evidence base.
  • It represents the second peer-reviewed, and third overall, clinical validation study demonstrating consistently excellent EsoGuard performance.
  • Soon to be released data from a fourth such clinical validation study tells the same story.

Pactiv Evergreen Inc. Declares Quarterly Dividend

Retrieved on: 
Thursday, May 2, 2024

LAKE FOREST, Ill., May 02, 2024 (GLOBE NEWSWIRE) -- Pactiv Evergreen Inc. (NASDAQ: PTVE) today announced that its board of directors has approved the payment of a quarterly dividend of $0.10 per share of common stock.

Key Points: 
  • LAKE FOREST, Ill., May 02, 2024 (GLOBE NEWSWIRE) -- Pactiv Evergreen Inc. (NASDAQ: PTVE) today announced that its board of directors has approved the payment of a quarterly dividend of $0.10 per share of common stock.
  • The dividend will be paid on June 14, 2024 to shareholders of record at the close of business on May 31, 2024.

Pactiv Evergreen Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
Weather, Food, Depreciation, Drink, Transport, Public expenditure, Three Months, EPS, Pactiv Evergreen, Growth, Video game

LAKE FOREST, Ill., May 02, 2024 (GLOBE NEWSWIRE) -- Pactiv Evergreen Inc. (“Pactiv Evergreen” or the “Company”) today reported results for the first quarter of 2024. Michael King, President and Chief Executive Officer of Pactiv Evergreen, said, “The first quarter presented us with a challenging business environment characterized by the cumulative effect of sustained price inflation on consumer spending and weather related disruptions. However, I am proud of our dedicated employees who remained focused on executing and delivering exceptional value to our customers, enabling us to achieve results at the high end of our guidance range for the first quarter. We continue to take decisive actions to navigate these headwinds and position our business for long-term growth. We expect that our strategy, which emphasizes innovation, operational excellence and customer service, will continue to enable us to align with industry leaders and drive volume growth. As we look to the second quarter and the remainder of the year, we believe that our resilient team, coupled with our strategic initiatives and cost initiatives, will allow us to capitalize on opportunities and deliver results for our stakeholders.”

Key Points: 
  • First Quarter 2024 Financial Highlights:
    Net Revenues of $1,252 million for the first quarter of 2024 were down 13% compared to $1,431 million in the first quarter of 2023 and down 2% compared to $1,274 million in the fourth quarter of 2023.
  • Adjusted EPS1 of $0.14 for the first quarter of 2024 compared to $0.13 in the first quarter of 2023 and $0.33 in the fourth quarter of 2023.
  • LAKE FOREST, Ill., May 02, 2024 (GLOBE NEWSWIRE) -- Pactiv Evergreen Inc. (“Pactiv Evergreen” or the “Company”) today reported results for the first quarter of 2024.
  • First Quarter 2024 Results vs. First Quarter 2023 Results
    Net revenues in the first quarter of 2024 were $1,252 million compared to $1,431 million in the first quarter of 2023.

Del Taco Opens Eighth Location in the Sunshine State

Retrieved on: 
Thursday, May 2, 2024
Lettuce, Environment, Crinkle-cutting, Cheese, Queso blanco, Growth, Drink, Fast food

DEFUNIAK SPRINGS, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Del Taco , the nation’s second-largest Mexican quick service restaurant*, announced today the opening of its new Fresh Flex location at 2760 S. Hwy 331.

Key Points: 
  • DEFUNIAK SPRINGS, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Del Taco , the nation’s second-largest Mexican quick service restaurant*, announced today the opening of its new Fresh Flex location at 2760 S. Hwy 331.
  • The DeFuniak Springs restaurant will welcome guests with a contemporary and colorful interior design that visually brings to life Del Taco's commitment to freshness and quality.
  • “Following the incredible response to our Santa Rosa Beach location, we’re thrilled to build on our growth with the opening of our second Del Taco restaurant in DeFuniak Springs,” said a spokesperson for Consolidated Taco Holdings.
  • For those interested in joining the DeFuniak Springs Del Taco team, positions are listed at http://www.deltaco.com/careers .

Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024

Retrieved on: 
Thursday, April 25, 2024
ASRT, Software, ID, Patient, Telephone, Webcast

LAKE FOREST, Ill., April 25, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release first quarter 2024 financial results on Monday, May 6, 2024, after the market close.

Key Points: 
  • LAKE FOREST, Ill., April 25, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release first quarter 2024 financial results on Monday, May 6, 2024, after the market close.
  • Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
  • To access the live webcast, conference call information, and other materials, please visit Assertio’s investor relations website at http://investor.assertiotx.com/overview/default.aspx .
  • A webcast replay of the call will be available approximately two hours after the call on Assertio’s investor website.

Pactiv Evergreen Inc. Schedules First Quarter 2024 Financial Results

Retrieved on: 
Thursday, April 18, 2024

LAKE FOREST, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Pactiv Evergreen (NASDAQ: PTVE) today announced the following details for its first quarter 2024 earnings release and teleconference call.

Key Points: 
  • LAKE FOREST, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Pactiv Evergreen (NASDAQ: PTVE) today announced the following details for its first quarter 2024 earnings release and teleconference call.
  • To join by phone, participants can register for the call here .
  • It is recommended that participants register at least 15 minutes before the call.
  • Once registered, participants will receive an email with the dial-in information.

Omar's Exotic Birds: The Premier Destination for Bird Enthusiasts, Launches New Online Store

Retrieved on: 
Friday, March 15, 2024
Exotic Birds, Attention, Behavior, Bird, Coffee

Founded nearly three decades ago by aviculture expert Omar Gonzalez, Omar's Exotic Birds has become synonymous with excellence in bird care.

Key Points: 
  • Founded nearly three decades ago by aviculture expert Omar Gonzalez, Omar's Exotic Birds has become synonymous with excellence in bird care.
  • The launch of the online store marks a significant milestone in Omar's Exotic Birds' journey to make quality avian products accessible to bird lovers everywhere.
  • "At Omar's Exotic Birds, we are passionate about providing bird enthusiasts with the resources they need to care for their avian companions," said Omar Gonzalez, founder of Omar's Exotic Birds.
  • In addition to its wide range of products, Omar's Exotic Birds' online store will offer valuable resources and information on bird care, behavior, and nutrition.

Sig Kirk Joins Assertio Board of Directors

Retrieved on: 
Wednesday, April 3, 2024
AbbVie, Financial management, Certification, Barr Pharmaceuticals, Audit, Business administration, Patient, Pace University, ASRT, Compensation, Allergan, CPA

LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced effectiveness of the appointment of Sigurd (Sig) Kirk to its board of directors.

Key Points: 
  • LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced effectiveness of the appointment of Sigurd (Sig) Kirk to its board of directors.
  • Kirk is a senior corporate business development executive with more than 20 years of pharmaceutical experience in the areas of branded biopharmaceutical, medical device and generic products.
  • Mr. Kirk started his career at Deloitte & Touche as an Audit Manager, earning his CPA certification.
  • “Both Sig’s appointment and the addition of Sravan Emany last fall demonstrate our ongoing commitment to aligning our board expertise with our evolving business strategies.”

Assertio to Present at LD Micro Invitational Conference in New York City

Retrieved on: 
Monday, April 1, 2024
Patient, Conference, ASRT, Software

LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the LD Micro Invitational XIV Conference to be held April 9, 2024 in New York City.

Key Points: 
  • LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the LD Micro Invitational XIV Conference to be held April 9, 2024 in New York City.
  • The Company will host a group presentation at 4:00 pm Eastern Time, and be available for individual meetings throughout the day.
  • Attending investors interested in meeting with the Company can request a meeting on the conference platform, or contact Assertio investor relations via [email protected] .
  • Presentation information will be available on the day of the event and can accessed at https://investor.assertiotx.com .